Home Healthcare Medical Devices Cyclosporine Market

Cyclosporine Market Size, Share & Trends Analysis Report By Indication (Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye Disease, Other Indication), By Route of Administration (Oral, Parenteral) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Cyclosporine Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Transplant Rejection Prophylaxis
    2. Rheumatoid Arthritis
    3. Psoriasis
    4. Autoimmune Myasthenia Gravis
    5. Dry Eye Disease
    6. Other Indication
  2. Cyclosporine Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Parenteral
  3. Regional Cyclosporine Market
    1. North America
      1. North America Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      2. North America Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
      3. U.S.
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      4. Canada
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
    2. Europe
      1. Europe Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      2. Europe Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
      3. U.K.
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      4. Germany
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      5. France
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      6. Spain
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      7. Italy
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      8. Russia
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      9. Nordic
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      10. Benelux
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      11. Rest of Europe
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
    3. APAC
      1. APAC Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      2. APAC Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
      3. China
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      4. Korea
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      5. Japan
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      6. India
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      7. Australia
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      8. Taiwan
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      9. South East Asia
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      10. Rest of Asia-Pacific
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
    4. Middle East and Africa
      1. Middle East and Africa Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      2. Middle East and Africa Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
      3. UAE
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      4. Turkey
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      5. Saudi Arabia
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      6. South Africa
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      7. Egypt
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      8. Nigeria
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      9. Rest of MEA
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
    5. LATAM
      1. LATAM Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      2. LATAM Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
      3. Brazil
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      4. Mexico
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      5. Argentina
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      6. Chile
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      7. Colombia
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
      8. Rest of LATAM
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
        7. Oral
        8. Parenteral
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.